ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
about
Hodgkin lymphoma, version 2.2015.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin disease-an ever-evolving therapy.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment.The GHSG Approach to Treating Hodgkin's Lymphoma.Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry.Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.New agents in relapsed/refractory Hodgkin's lymphoma.First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.
P2860
Q30769157-DB3A4A99-5C5D-405E-9D4F-4C4EDB79A24AQ33704061-FE5C9EDA-4835-462E-9D79-F59EA1116295Q34194160-81243463-31BD-4757-A91A-C3DC334F0F30Q34463426-20D5F041-52F2-49D3-84D1-A35B52BFE032Q37126978-D9507281-DCEA-471D-A0FF-43DF15C8E9DAQ37694536-18BFD380-4298-41D6-87B8-7CF99AFF1ABEQ38337152-AED6DE47-B761-4005-9A62-4D2799DDDE49Q38506223-900A5EAD-9C36-41BA-9EE8-750F5627D557Q38712597-1F16EB65-405E-474D-9F40-75EA3B20DAC4Q38929198-B1724B38-46AB-404C-95EA-E161FD396280Q39208496-C1488771-BADC-4DB7-ACC5-BE8D750DB7BDQ39995834-4E96AE09-739F-48AD-8E1F-ADD9DDD3D296Q40044179-7318FF8F-41F8-46C3-84B4-01897E7C1507Q40499200-C95166C1-C9F9-4D00-AB39-7FC637704D22Q41378943-CEE60BD3-5DFB-4002-8770-510201718F5AQ41500227-B03F8963-7D85-44BE-8BC3-3321E5EA3E5EQ48921913-C1727028-54D7-482B-A290-30B30DE827B2
P2860
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
ABVD (8 cycles) versus BEACOPP ...... the LYSA H34 randomized trial.
@en
ABVD
@nl
type
label
ABVD (8 cycles) versus BEACOPP ...... the LYSA H34 randomized trial.
@en
ABVD
@nl
prefLabel
ABVD (8 cycles) versus BEACOPP ...... the LYSA H34 randomized trial.
@en
ABVD
@nl
P2093
P2860
P50
P356
P1433
P1476
ABVD (8 cycles) versus BEACOPP ...... the LYSA H34 randomized trial
@en
P2093
A Aoudjhane
C Humbrecht
E Nicolas-Virelizier
I Gaillard
Lymphoma Study Association (LYSA)
P2860
P304
P356
10.1093/ANNONC/MDU189
P577
2014-05-14T00:00:00Z